GlassScriptPhysician profile
James Kenneth Chang
NPI 1053501916
$2,395.12
in general payments reported to CMS, 2019-2025
20 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $61.69 · 2021: $395 · 2022: $886 · 2023: $463 · 2024: $321 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $910.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $657.25 | 2022-2024 | Exparel, Iovera, Zilretta |
| Collegium Pharmaceutical, INC. | $526.71 | 2019-2023 | Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $339.11 | 2023-2025 | Relistor |
| Biohaven Pharmaceuticals, INC. | $278.85 | 2021 | |
| Nalu Medical, INC. | $199.85 | 2023 | Nalu Neurostimulation System |
| Fidia Pharma USA INC. | $61.83 | 2021-2023 | Hymovis, Triluron |
| Hikma Pharmaceuticals USA | $54.28 | 2022 | |
| Djo, LLC | $45.83 | 2024 | Cmf |
| Bioventus LLC | $45.29 | 2025 | Durolane |
| Depuy Synthes Sales INC. | $34.68 | 2020-2022 | |
| Protega Pharmaceutials INC | $18.39 | 2023 | Roxybond |
| Biohaven Pharmaceutical Holding Company LTD. | $17.82 | 2022 | |
| Indivior INC. | $16.57 | 2019 | |
| Highridge Medical LLC | $15.86 | 2024 | Biomet Spinalpak Non-Invasive Spine Fusion Stimulator System |
| Forte Bio-Pharma LLC | $15.32 | 2025 | Prolate, Nalocet, Tanlor |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $15.03 | 2025 | Ams 700 |
| Mdd US Operations, LLC | $14.61 | 2019 | |
| Pfizer INC. | $13.91 | 2023 | |
| Daiichi Sankyo INC. | $12.77 | 2019 | |
| Redhill Biopharma INC. | $11.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.